dostęp otwarty
Atypowe leki przeciwpsychotyczne w leczeniu choroby afektywnej dwubiegunowej
dostęp otwarty
Streszczenie
Streszczenie
Słowa kluczowe
atypowe leki przeciwpsychotyczne; choroba afektywna dwubiegunowa
Tytuł
Atypowe leki przeciwpsychotyczne w leczeniu choroby afektywnej dwubiegunowej
Czasopismo
Numer
Typ artykułu
Artykuł przeglądowy
Strony
1-7
Opublikowany online
2004-04-26
Wyświetlenia strony
954
Wyświetlenia/pobrania artykułu
6012
Rekord bibliograficzny
Psychiatria 2004;1(1):1-7.
Słowa kluczowe
atypowe leki przeciwpsychotyczne
choroba afektywna dwubiegunowa
Autorzy
Barbara Sęp-Kowalikowa
Monika Czucha
- Greenblatt HK, Greenblatt DJ. Gabapentin and Pregabalin for the Treatment of Anxiety Disorders. Clin Pharmacol Drug Dev. 2018; 7(3): 228–232.
- Moon DE, Lee DIk, Lee SC, et al. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study. Clin Ther. 2010; 32(14): 2370–2385.
- Mayor S. Pregabalin and gabapentin become controlled drugs to cut deaths from misuse. BMJ. 2018; 363: k4364.
- Evoy KE, Morrison MD, Saklad SR. Abuse and Misuse of Pregabalin and Gabapentin. Drugs. 2017; 77(4): 403–426.
- Schjerning O, Pottegård A, Damkier P, et al. Use of pregabalin - a nationwide pharmacoepidemiological drug utilization study with focus on abuse potential. Pharmacopsychiatry. 2016; 49(4): 155–161.
- Generoso MB, Trevizol AP, Kasper S, et al. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. Int Clin Psychopharmacol. 2017; 32(1): 49–55.
- Montgomery SA, Lyndon G, Almas M, et al. Early improvement with pregabalin predicts endpoint response in patients with generalized anxiety disorder: an integrated and predictive data analysis. Int Clin Psychopharmacol. 2017; 32(1): 41–48.
- Jarema M. Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Via Medica, Gdańsk 2015.
- Tassone DM, Boyce E, Guyer J, et al. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007; 29(1): 26–48.
- Ströhle A, Gensichen J, Domschke K. The diagnosis and treatment of anxiety disorders. Dtsch Arztebl Int. 2018; 155(37): 611–620.
- Strawn JR, Geracioti L, Rajdev N, et al. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother. 2018; 19(10): 1057–1070.
- Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017; 19(2): 93–107.
- Perna G, Alciati A, Riva A, et al. Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review. Curr Psychiatry Rep. 2016; 18(3): 23.
- Meier SM, Petersen L, Mattheisen M, et al. Secondary depression in severe anxiety disorders: a population-based cohort study in Denmark. Lancet Psychiatry. 2015; 2(6): 515–523.
- Baldwin DS, den Boer JA, Lyndon G, et al. Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature. J Psychopharmacol. 2015; 29(10): 1047–1060.
- Baandrup L, Ebdrup BH, Rasmussen JØ, et al. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 2018; 3: CD011481.
- Ruiz MA, Álvarez E, Carrasco JL, et al. Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice. Drug Des Devel Ther. 2015; 9: 4329–4340.
- Ruiz M, Álvarez E, Carrasco J, et al. Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice. Drug Design, Development and Therapy. 2015: 4329.
- Martinotti G. Pregabalin in clinical psychiatry and addiction: pros and cons. Expert Opin Investig Drugs. 2012; 21(9): 1243–1245.
- Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf. 2014; 5(1): 38–56.
- Erdoğan C, Ongun N, Tümkaya S, et al. What is the real effect of pregabalin in patients with diabetic neuropathic pain?(Do patients suffer from less pain or do they less care about it?). Ideggyogy Sz. 2018; 71(5-06): 213–216.
- Ogawa S, Arakawa A, Hayakawa K, et al. Pregabalin for Neuropathic Pain: Why Benefits Could Be Expected for Multiple Pain Conditions. Clin Drug Investig. 2016; 36(11): 877–888.
- Kozubski W, Liberski P, Moryś J, Neurologia T. Neurologia. T. 1-2. PZWL, Warszawa 2013.
- Gaitatzis A, Trimble MR, Sander JW. The psychiatric comorbidity of epilepsy. Acta Neurol Scand. 2004; 110(4): 207–220.
- Swisher CB, Doreswamy M, Husain AM. Use of pregabalin for nonconvulsive seizures and nonconvulsive status epilepticus. Seizure. 2013; 22(2): 116–118.